RT Journal Article
SR Electronic
T1 Vagus nerve inflammation contributes to dysautonomia in COVID-19
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.06.14.23291320
DO 10.1101/2023.06.14.23291320
A1 Woo, Marcel S.
A1 Shafiq, Mohsin
A1 Fitzek, Antonia
A1 Dottermusch, Matthias
A1 Altmeppen, Hermann
A1 Mohammadi, Behnam
A1 Mayer, Christina
A1 Bal, Lukas C.
A1 Raich, Lukas
A1 Matschke, Jakob
A1 Krasemann, Susanne
A1 Pfefferle, Susanne
A1 Brehm, Thomas Theo
A1 Lütgehetmann, Marc
A1 Schädler, Julia
A1 Addo, Marylin M.
A1 Schulze Zur Wiesch, Julian
A1 Ondruschka, Benjamin
A1 Friese, Manuel A.
A1 Glatzel, Markus
YR 2023
UL http://medrxiv.org/content/early/2023/06/20/2023.06.14.23291320.abstract
AB Dysautonomia has substantially impacted acute COVID-19 severity as well as symptom burden after recovery from COVID-19 (long COVID), yet the underlying causes remain unknown. Here, we show that SARS-CoV-2 is detectable in postmortem vagus nerve specimen together with inflammatory cell infiltration derived primarily from monocytes. This is associated with a decreased respiratory rate in non-survivors of critical COVID-19. Our data suggest that SARS-CoV-2 induces vagus nerve inflammation followed by autonomic dysfunction.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was funded by the Deutsche Forschungsgemeinschaft (DFG; FR1720/18-1 to MAF and GL 589/10-1 to MG), the Federal Ministry of Education and Research within the framework of the network of university medicine (DEFEAT PANDEMICs, 01KX2021 and NATON, 01KX2121 to BO). MSW is supported by the Joachim-Herz-Foundation.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Institutional review board of the independent ethics committee of the Hamburg Chamber of Physicians (protocol nos. PV7311, 2020-10353-BO-ff, and PV5034)I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesThe RNA-sequencing data is available under the GEO accession number c. All other data is available from the corresponding author upon reasonable request.